|

CC-97540 Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: BMS-986353, Zola-cel, Zolacabtagene autoleucel

Pipeline

Phase 1: 2Phase 2: 1

Top Sponsors

  • Juno Therapeutics, Inc., a Bristol-Myers Squibb Company3

Indications

  • Lupus2
  • Idiopathic Inflammatory Myopathy1
  • Systemic Sclerosis1
  • Lupus Nephritis1
  • Lupus Erythematosus, Systemic1

Birmingham, Alabama2 trials

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Local Institution - 0009

Phase 2
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

University of Alabama at Birmingham

Phase 1

Aurora, Colorado1 trial

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

University of Colorado Anschutz Medical Campus

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.